- recruitingPHASE1, PHASE2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
This study is testing a new drug, BI-1808, by itself and with another medicine, pembrolizumab (Keytruda®), for people with advanced cancers. The goal is to see how safe the new drug is, what side effects it causes, and find the right dose for future studies.
United States · Denmark · Hungary - enrolling by invitationPHASE2
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
This study is checking on people who have had a special treatment called AUTO CAR T cell therapy. Doctors want to see how these patients are doing for up to 15 years after their treatment. This helps them understand the long-term effects of this new therapy for blood cancers.
United States · United Kingdom